Cerenome (CNSY) vs Tempest Therapeutics (TPST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cerenome (CNSY) has outperformed Tempest Therapeutics (TPST) over the past year, losing 89.3% versus a loss of 92.9%. Over five years, TPST leads with a -99.6% price change compared with -99.7% for CNSY. Cerenome is the larger company by market cap ($14.6 million vs $12.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNSY | TPST |
|---|---|---|
| Share price | $1.93 | $0.7601 |
| Market cap | $14.65M | $12.84M |
| 1-day change | +7.82% | -1.29% |
| YTD return | -84.86% | -73.52% |
| 1-year return | -89.28% | -92.95% |
| 5-year return | -99.71% | -99.60% |
| EPS (TTM) | $-3.36 | $-3.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.00 | $12.23 |
| 52-week low | $1.49 | $0.743 |
| Distance from 52-week high | -89.84% | -93.78% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1337.82% | +820.93% |
| Average volume | 121.94K | 2.64M |
| Shares outstanding | 7.59M | 16.89M |
| Employees | 28 | 4 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cerenome
CNSY stock →Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Health Care · Medical/Dental Instruments · 28 employees
About Tempest Therapeutics
TPST stock →Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
CNSY vs TPST FAQ
Which is bigger, Cerenome or Tempest Therapeutics?
Cerenome (CNSY) is larger, with a market capitalization of $14.65M compared with $12.84M for Tempest Therapeutics (TPST).
Which stock has performed better over the past year, CNSY or TPST?
CNSY returned -89.28% over the past 12 months, compared with -92.95% for TPST (price return, excluding dividends). Past performance does not predict future results.
Are Cerenome and Tempest Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Cerenome and Biotechnology: Pharmaceutical Preparations for Tempest Therapeutics.